Secondary chemoprevention of Barrett's esophagus with celecoxib: Results of a randomized trial Academic Article uri icon

Overview

MeSH Major

  • Barrett Esophagus
  • Cyclooxygenase Inhibitors
  • Esophageal Neoplasms
  • Precancerous Conditions
  • Pyrazoles
  • Sulfonamides

abstract

  • Administration of 200 mg of celecoxib twice daily for 48 weeks of treatment does not appear to prevent progression of Barrett's dysplasia to cancer.

publication date

  • April 4, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3755596

Digital Object Identifier (DOI)

  • 10.1093/jnci/djk112

PubMed ID

  • 17405999

Additional Document Info

start page

  • 545

end page

  • 57

volume

  • 99

number

  • 7